|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
11
|
|
pubmed:dateCreated |
2009-12-24
|
|
pubmed:abstractText |
Imexon is an aziridine-containing small pro-oxidant molecule with promising antitumor activity in myeloma, lymphoma and lung and pancreatic cancer. Imexon is already in clinical trials in patients with advanced solid tumors. The present study examined the effects of imexon on H9 and Raji lymphoma cell lines in vitro when given in combination with ionizing radiation.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
1791-7530
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
29
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
4409-15
|
|
pubmed:meshHeading |
pubmed-meshheading:20032386-Apoptosis,
pubmed-meshheading:20032386-Blotting, Western,
pubmed-meshheading:20032386-Cell Cycle,
pubmed-meshheading:20032386-Cell Line, Tumor,
pubmed-meshheading:20032386-Combined Modality Therapy,
pubmed-meshheading:20032386-Hexanones,
pubmed-meshheading:20032386-Humans,
pubmed-meshheading:20032386-Lymphoma, Non-Hodgkin,
pubmed-meshheading:20032386-Lymphoma, T-Cell,
pubmed-meshheading:20032386-Oxidation-Reduction,
pubmed-meshheading:20032386-Radiation-Sensitizing Agents
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Imexon augments sensitivity of human lymphoma cells to ionizing radiation: in vitro experimental study.
|
|
pubmed:affiliation |
Department of Experimental Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
